Another retrospective study using BI-RADS for MD assessment did not find such an association [22]; however, it was based on a cohort that was different from many others—a low pCR rate (15%), suboptimal NACT (i.e., no anti-HER2 treatment to patients with HER2-overexpressing tumors), and a pCR definition that included patients with residual invasive tumor cells making comparison with other studies difficult. The gene discussed is ERBB2; the disease is neoplasm.